Jul 21 |
Wall Street Breakfast: The Week Ahead
|
Jul 9 |
CG Oncology Bringing Undervalued Innovation To Bladder Cancer
|
Jun 18 |
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
|
Jun 6 |
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
|
May 24 |
CG Oncology climbs 10% on Phase 2 data for bladder cancer drug
|
May 24 |
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
|
May 13 |
CG Oncology upgraded by Goldman Sachs on recent clinical data
|
May 9 |
CG Oncology, Inc. reports Q1 results
|
May 9 |
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
|
May 6 |
CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value
|